You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2004–09
TO BE UPDATED FOR 2011!
Notes:
1. The trends represent the available information on national street-level prices for each drug in the EU Member States and Norway, weighted by country population sizes to form an overall EU trend. Prices have been adjusted for national inflation rates (base year 2004) and all series indexed to a base of 100 in 2004.
2. Countries missing drug price information for two or more consecutive years are not included in the trend calculations: the trend for LSD is based on twelve countries (82 % of the EU population 15-64), amphetamine on thirteen countries (81 % of the EU population 15-64), cocaine on fifteen countries (88 % of the EU population 15-64), ecstasy on sixteen countries (88 % of the EU population 15-64), herbal cannabis on seventeen countries (88 % of the EU population 15-64), and cannabis resin on eighteen countries (91 % of the EU population 15-64). Trends for other drugs are not available due to insufficient data.
3. Additionally, where 2009 data are missing (twenty cases) 2008 prices are used; for missing 2004 data (sixteen cases) 2005 prices are used; data missing for other years (sixteen cases) have been interpolated from adjacent years.
Sources:
Price data: Reitox national focal points
(see the help page for information about formats etc.)